Evidence map›Paper›PMID 37950840›Full record

ArticleFolia microbiologica2023

Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.

Thaís C Pereira, Paulo H F do Carmo, Raquel T de Menezes, Haroldo C de Oliveira, Luciane D de Oliveira, Juliana C Junqueira, Liliana Scorzoni

Erratum issuedOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Thaís C PereiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil.ORCID http://orcid.org/0000-0002-7206-3348
Paulo H F do CarmoDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil.ORCID http://orcid.org/0000-0003-3186-885X
Raquel T de MenezesDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil.ORCID http://orcid.org/0000-0003-4250-5528
Haroldo C de OliveiraInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.ORCID http://orcid.org/0000-0001-5760-4209
Luciane D de OliveiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil.ORCID http://orcid.org/0000-0001-9956-7768
Juliana C JunqueiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil.ORCID http://orcid.org/0000-0001-6646-6856
Liliana ScorzoniDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos, SP, 12245-000, Brazil. liliscorzoni@yahoo.com.br.ORCID http://orcid.org/0000-0002-0178-6653
Universidade Estadual Paulista (Unesp) · BRFundação Oswaldo Cruz · BRGuarulhos University · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptococcus neoformans is an encapsulated yeast that can cause cryptococcosis and cryptococcal meningitis, which conventional treatment involves antifungal drugs such as polyenes, flucytosine, azoles, and their combinations. However, the high cost, toxicity, and increase in fungi resistance to antifungal agents stimulate the search for therapeutic strategies such as drug repurposing and combination therapy. This study evaluated the activity of the antihypertensive verapamil (VEH) alone and combined with amphotericin B (AmB) against C. neoformans. VEH exhibited antifungal activity against C. neoformans with minimum inhibitory concentration and minimum fungicidal concentration of 118 µg per mL. The combination of VEH and AmB exhibited synergism, reducing at least eightfold both drugs' concentrations. Moreover, the combination decreased the size and glucuronoxylomannnan content of C. neoformans capsule. However, no difference was observed in ergosterol levels of C. neoformans after treatment with VEH and AmB in combination. Altogether, VEH in combination with AmB exhibits potential as a candidate as for the development of anti-cryptococcal drug.

Indexed as

CryptococcosisCryptococcus neoformansAmphotericin BAntifungal AgentsFlucytosineMicrobial Sensitivity TestsAmphotericin BAntifungal AgentsFlucytosineAntifungalCapsuleCryptococcus neoformansSynergismVerapamil

Identifiers

PMID37950840
OpenAlexW4388586268

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.